{"id":18762,"date":"2025-03-26T15:35:29","date_gmt":"2025-03-26T14:35:29","guid":{"rendered":"https:\/\/www.medipan.de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/"},"modified":"2025-11-26T10:28:27","modified_gmt":"2025-11-26T09:28:27","slug":"new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy","status":"publish","type":"post","link":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/","title":{"rendered":"Neue diagnostische Erkenntnisse beim Antiphospholipid-Syndrom (APS) und Schwangerschaft"},"content":{"rendered":"\n<p>Das Antiphospholipid-Syndrom (APS) ist eine komplexe Autoimmunerkrankung, die erhebliche diagnostische und therapeutische Herausforderungen mit sich bringt, insbesondere in der Schwangerschaft. J\u00fcngste Forschungen haben neue Erkenntnisse zur Diagnostik, Klassifikation und Prognose des APS geliefert, was zu einem verfeinerten Ansatz in der Patientenversorgung gef\u00fchrt hat.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Verfeinerungen der Klassifikationskriterien f\u00fcr das Antiphospholipid-Syndrom (APS)<\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/APS-2-1024x1024.png\" alt=\"\" class=\"wp-image-103213\" style=\"width:371px;height:auto\" srcset=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/APS-2-1024x1024.png 1024w, https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/APS-2-300x300.png 300w, https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/APS-2-150x150.png 150w, https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/APS-2-768x768.png 768w, https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/APS-2-1536x1536.png 1536w, https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/APS-2-2048x2048.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n\n\n<p><a href=\"http:\/\/pubmed.ncbi.nlm.nih.gov\/37635643\/\">http:\/\/pubmed.ncbi.nlm.nih.gov\/37635643\/<\/a>Ein entscheidender Fortschritt in der Diagnose des Antiphospholipid-Syndroms (APS) ist die \u00dcberarbeitung der <a href=\"http:\/\/Barbhaiya, et al. (2024). The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria\">Klassifikationskriterien<\/a> durch das American College of Rheumatology (ACR) und die European League Against Rheumatism (EULAR). Diese f\u00fchrten ein gewichtsbasierendes Modell ein, das klinische und laborchemische Befunde priorisiert. Die neuen Kriterien betonen die Bedeutung der Unterscheidung von obstetrischem APS gegen\u00fcber anderen Manifestationen und beinhalten schwangerschaftsbedingte Komplikationen wie fetale Wachstumsrestriktion und schwere Pr\u00e4eklampsie, um APS-Subtypen besser abzugrenzen.<\/p>\n\n\n\n<p>Zu den Laboruntersuchungen geh\u00f6ren der Lupus-Antikoagulans-Test (LAC), IgG\/IgM-Antikardiolipin-Antik\u00f6rper (aCL) sowie IgG\/IgM-Anti-\u03b22-Glykoprotein-I-Antik\u00f6rper (anti-\u03b22GPI), wobei mindestens ein positiver Befund f\u00fcr die Klassifikation erforderlich ist. F\u00fcr einen standardisierten Ansatz sollte ein Enzymimmunoassay (ELISA) zur Bestimmung antiphospholipider Antik\u00f6rper verwendet werden.<sup data-fn=\"1a6564a0-1e4e-46b7-93a4-03227522d30f\" class=\"fn\"><a id=\"1a6564a0-1e4e-46b7-93a4-03227522d30f-link\" href=\"#1a6564a0-1e4e-46b7-93a4-03227522d30f\">1<\/a><\/sup> Obwohl die Klassifikationskriterien nicht mit den diagnostischen Kriterien gleichzusetzen sind, ist ihre klinische Relevanz f\u00fcr die Patientenbewertung und -behandlung offensichtlich. Um diese Kriterien mit anderen g\u00e4ngigen Testmethoden abzugleichen, hat eine Expertengruppe das Ziel gesetzt, die Harmonisierung zwischen APS-Antik\u00f6rper-ELISA- und Nicht-ELISA-Techniken zu verbessern.<sup data-fn=\"cef8f728-df1b-4004-b67c-8ba0f37ebc6d\" class=\"fn\"><a id=\"cef8f728-df1b-4004-b67c-8ba0f37ebc6d-link\" href=\"#cef8f728-df1b-4004-b67c-8ba0f37ebc6d\">2<\/a><\/sup><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Antiphospholipid-Syndrom (APS)-Subgruppen und Risikostratifizierung<\/h2>\n\n\n\n<p>Mithilfe einer maschinellen Lernanalyse konnten drei eindeutige APS-Subgruppen identifiziert werden, wobei ein klarer Unterschied zwischen obstetrischem und thrombotischem APS besteht. Zudem zeigt sich bei thrombotischem APS eine geschlechtsspezifische Differenzierung zwischen M\u00e4nnern und Frauen. Die Patienten k\u00f6nnen anhand klinischer Merkmale und biomolekularer Marker stratifiziert werden, was eine pr\u00e4zisere prognostische Einsch\u00e4tzung erm\u00f6glicht. Beispielsweise weisen einige APS-Patienten ein vorwiegend obstetrisches Profil mit hoher Schwangerschaftsmorbidit\u00e4t, aber einem geringeren Thromboserisiko auf, w\u00e4hrend andere schwere thrombotische Komplikationen entwickeln, die eine aggressivere Behandlungsstrategie erfordern.<sup data-fn=\"4dfe3542-aee0-4f15-b5bc-3426cc197f65\" class=\"fn\"><a id=\"4dfe3542-aee0-4f15-b5bc-3426cc197f65-link\" href=\"#4dfe3542-aee0-4f15-b5bc-3426cc197f65\">3<\/a><\/sup><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Neue Biomarker zur APS-Diagnose<\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignleft size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"876\" src=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/Bild1-1024x876.png\" alt=\"\" class=\"wp-image-18575\" style=\"width:310px;height:auto\" srcset=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/Bild1-1024x876.png 1024w, https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/Bild1-300x257.png 300w, https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/Bild1-768x657.png 768w, https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/Bild1.png 1052w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n\n\n<p class=\"has-text-align-left\">Neue Biomarker f\u00fcr APS-Patienten mit vaskul\u00e4rer Thrombose und\/oder schwangerschaftsbedingten Komplikationen verbessern die Risikobewertung in der Diagnostik. Der Lupus-Antikoagulans-Test (LAC) bleibt der wichtigste Pr\u00e4diktor f\u00fcr ung\u00fcnstige Schwangerschaftsausg\u00e4nge, darunter fetale Wachstumsrestriktion und wiederholte Fehlgeburten. Neben Antikardiolipin-Antik\u00f6rpern (aCL) und Anti-\u03b22-Glykoprotein-I-Antik\u00f6rpern (anti-\u03b22GPI) gewinnen weitere spezifische Antik\u00f6rper, die als \u201eNon-Kriterien-APS\u201c bezeichnet werden, zunehmend an Bedeutung f\u00fcr eine verfeinerte Risikostratifizierung.<sup data-fn=\"352b2b96-b8e0-4a7e-b323-6e7b857157a1\" class=\"fn\"><a id=\"352b2b96-b8e0-4a7e-b323-6e7b857157a1-link\" href=\"#352b2b96-b8e0-4a7e-b323-6e7b857157a1\">4<\/a><\/sup> Unterschiede in den Antiphospholipid-Antik\u00f6rper-Profilen wurden zwischen Patienten mit obstetrischem und thrombotischem APS festgestellt. Diese Biomarker tragen zur zunehmenden Betonung personalisierter Behandlungsstrategien bei, um sicherzustellen, dass Hochrisikopatienten gezielte therapeutische Interventionen erhalten.<sup data-fn=\"924b3cd8-f300-46db-af18-4d0b48e3e240\" class=\"fn\"><a id=\"924b3cd8-f300-46db-af18-4d0b48e3e240-link\" href=\"#924b3cd8-f300-46db-af18-4d0b48e3e240\">5<\/a><\/sup><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Fazit<\/h2>\n\n\n\n<p>Diese Fortschritte stellen einen bedeutenden Schritt nach vorn in der Diagnose und Behandlung des Antiphospholipid-Syndroms (APS) dar. Die Integration verfeinerter Klassifikationssysteme, neuer Biomarker und maschineller Lernmethoden zur Patientenstratifizierung erm\u00f6glicht eine pr\u00e4zisere Risikobewertung und personalisierte Therapieans\u00e4tze. Mit fortschreitender Forschung werden diese Erkenntnisse voraussichtlich zu verbesserten klinischen Ergebnissen f\u00fcr APS-Patienten, insbesondere w\u00e4hrend der Schwangerschaft, f\u00fchren.<\/p>\n\n\n\n<p><\/p>\n\n\n<div class=\"wp-block-post-date\"><time datetime=\"2025-03-26T15:35:29+01:00\">26. M\u00e4rz 2025<\/time><\/div>\n\n\n<p><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Related products<\/h4>\n\n\n\n<head>\n    <meta charset=\"UTF-8\">\n    <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\n    <title>Tabella APS<\/title>\n    <style>\n        .wp-block-table table.has-fixed-layout {\n            width: 100%;\n            border-collapse: collapse;\n        }\n        .wp-block-table table.has-fixed-layout col:first-child {\n            width: 25%;\n        }\n        .wp-block-table table.has-fixed-layout td, \n        .wp-block-table table.has-fixed-layout th {\n            border: 1px solid #ddd;\n            padding: 8px;\n        }\n        .wp-block-table table.has-fixed-layout th {\n            background-color: #f4f4f4;\n        }\n        .wp-block-table table.has-fixed-layout td:first-child {\n            white-space: nowrap; \/* Evita che il testo vada a capo *\/\n        }\n    <\/style>\n<\/head>\n<body>\n\n<figure class=\"wp-block-table\">\n    <table class=\"has-fixed-layout\">\n        <colgroup>\n            <col style=\"width: 40%;\">\n            <col style=\"width: 60%;\">\n        <\/colgroup>\n        <tbody>\n            <tr>\n                <th>Name<\/th>\n                <th>Beschreibung<\/th>\n            <\/tr>\n            <tr>\n                <td><a href=\"https:\/\/www.medipan.de\/de\/products\/4014-anti-cardiolipin-screen\/\" target=\"_blank\" rel=\"noreferrer noopener\">4014 &#8211; Anti-Cardiolipin Screen<\/a><\/td>\n                <td>ELISA zur Bestimmung von Antikardiolipin-Antik\u00f6rpern (IgG, IgM und IgA). (<em>IgG, IgM and IgA<\/em>).<\/td>\n            <\/tr>\n            <tr>\n                <td><a href=\"https:\/\/www.medipan.de\/de\/products\/4016-anti-cardiolipin\/\" target=\"_blank\" rel=\"noreferrer noopener\">4016 &#8211; Anti-Cardiolipin<\/a><\/td>\n                <td>ELISA zur Bestimmung von Antikardiolipin-Antik\u00f6rpern. (<em>IgG or IgM<\/em>).<\/td>\n            <\/tr>\n            <tr>\n                <td><a href=\"https:\/\/www.medipan.de\/de\/products\/4036-anti-ss2-gp-i-screen\/\" target=\"_blank\" rel=\"noreferrer noopener\">4036 &#8211; Anti-\u03b22-GP-I Screen<\/a><\/td>\n                <td>ELISA zur Bestimmung von Anti-\u03b22-Glykoprotein-I-Antik\u00f6rpern. (<em>IgG, IgM and IgA<\/em>).<\/td>\n            <\/tr>\n            <tr>\n                <td><a href=\"https:\/\/www.medipan.de\/de\/products\/4041-anti-ss2-gp-i\/\" target=\"_blank\" rel=\"noreferrer noopener\">4041 &#8211; Anti-\u03b22-GP-I<\/a><\/td>\n                <td>ELISA zur Bestimmung von Anti-\u03b22-Glykoprotein-I-Antik\u00f6rpern. (<em>IgG or IgM<\/em>).<\/td>\n            <\/tr>\n            <tr>\n                <td><a href=\"https:\/\/www.medipan.de\/de\/products\/4050-anti-phospholipid-screen\/\" target=\"_blank\" rel=\"noreferrer noopener\">4050 &#8211; Anti-Phospholipid screen<\/a><\/td>\n                <td>ELISA zur Bestimmung von Antiphospholipid-Antik\u00f6rpern [Kardiolipin, Phosphatidylserin, -inositol, -ethanolamin, Phosphatids\u00e4ure] (<em>IgG or IgM<\/em>).<\/td>\n            <\/tr>\n            <tr>\n                <td><a href=\"https:\/\/www.medipan.de\/de\/products\/4056-anti-phosphatidyl-serin\/\" target=\"_blank\" rel=\"noreferrer noopener\">4056 &#8211; Anti-Phosphatidyl-serin<\/a><\/td>\n                <td>ELISA zur Bestimmung von Anti-Phosphatidylserin-Antik\u00f6rpern. (<em>IgG or IgM<\/em>).<\/td>\n            <\/tr>\n        <\/tbody>\n    <\/table>\n<\/figure>\n\n<\/body>\n\n\n\n<!DOCTYPE html>\n<html lang=\"it\">\n<head>\n    <meta charset=\"UTF-8\">\n    <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\n    <title>Tabella APS<\/title>\n    <style>\n        .wp-block-table table.has-fixed-layout {\n            width: 100%;\n            border-collapse: collapse;\n        }\n        .wp-block-table table.has-fixed-layout col:first-child {\n            width: 25%;\n        }\n        .wp-block-table table.has-fixed-layout td, \n        .wp-block-table table.has-fixed-layout th {\n            border: 1px solid #ddd;\n            padding: 8px;\n        }\n        .wp-block-table table.has-fixed-layout th {\n            background-color: #f4f4f4;\n        }\n        .wp-block-table table.has-fixed-layout td:first-child {\n            white-space: nowrap; \/* Evita che il testo vada a capo *\/\n        }\n    <\/style>\n<\/head>\n<body>\n\n<figure class=\"wp-block-table\">\n    <table class=\"has-fixed-layout\">\n        <colgroup>\n            <col style=\"width: 40%;\">\n            <col style=\"width: 60%;\">\n        <\/colgroup>\n        <tbody>\n            <tr>\n                <th>Name<\/th>\n                <th>Beschreibung<\/th>\n            <\/tr>\n            <tr>\n                <td><a href=\"https:\/\/www.medipan.de\/de\/products\/5012-anti-phospholipid-10-dot\/\" target=\"_blank\" rel=\"noreferrer noopener\">5012 &#8211; Anti-Phospholipid 10 Dot<\/a><\/td>\n                <td>Immunoblot zur Profilbestimmung von Antik\u00f6rpern gegen Phospholipide und Serumproteine [Kardiolipin, Phosphatids\u00e4ure, Phosphatidylcholin, -ethanolamin, -glycerol, -inositol, -serin, Annexin V, \u03b22GP I, Prothrombin] (<em>IgG or IgM<\/em>).<\/td>\n            <\/tr>\n            <tr>\n                <td><a href=\"https:\/\/www.medipan.de\/de\/products\/50401-dotdiver-anti-phospholipid-igg\/\" target=\"_blank\" rel=\"noreferrer noopener\">50401 &#8211; DotDiver Anti-Phospholipid IgG<\/a><\/td>\n                <td>Immunoblot zur Profilbestimmung von Antik\u00f6rpern gegen Phospholipide und Serumproteine [Kardiolipin, Phosphatids\u00e4ure, Phosphatidylethanolamin, -glycerol, -inositol, -serin, Annexin V, \u03b22-GP I, Prothrombin](<em>IgG<\/em>) f\u00fcr den Einsatz in automatisierten Systemen <a href=\"https:\/\/www.medipan.de\/de\/products\/5075-dotdiver2-0\/\" target=\"_blank\" rel=\"noreferrer noopener\">DotDiver2.0<\/a>.<\/td>\n            <\/tr>\n            <tr>\n                <td><a href=\"https:\/\/www.medipan.de\/de\/products\/50411-dotdiver-anti-phospholipid-igm\/\" target=\"_blank\" rel=\"noreferrer noopener\">50411 &#8211; DotDiver Anti-Phospholipid IgM<\/a><\/td>\n                <td>Immunoblot zur Profilbestimmung von Antik\u00f6rpern gegen Phospholipide und Serumproteine [Kardiolipin, Phosphatids\u00e4ure, Phosphatidylethanolamin, -glycerol, -inositol, -serin, Annexin V, \u03b22-GP I, Prothrombin] (<em>IgM<\/em>) und f\u00fcr den Einsatz in automatisierten Systemen <a href=\"https:\/\/www.medipan.de\/de\/products\/5075-dotdiver2-0\/\" target=\"_blank\" rel=\"noreferrer noopener\">DotDiver2.0<\/a>.<\/td>\n            <\/tr>\n        <\/tbody>\n    <\/table>\n<\/figure>\n\n<\/body>\n<\/html>\n\n\n\n<p><\/p>\n\n\n<ol class=\"wp-block-footnotes\"><li id=\"1a6564a0-1e4e-46b7-93a4-03227522d30f\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37635643\/\" target=\"_blank\" rel=\"noreferrer noopener\">Barbhaiya, <em>et al.<\/em> (2024). The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria<\/a> <a href=\"#1a6564a0-1e4e-46b7-93a4-03227522d30f-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 1 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"cef8f728-df1b-4004-b67c-8ba0f37ebc6d\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39395544\/\" target=\"_blank\" rel=\"noreferrer noopener\">Meroni, <em>et al.<\/em> (2025). American College of Rheumatology\/European League Against Rheumatism antiphospholipid syndrome classification criteria solid phase-based antiphospholipid antibody domain-collaborative efforts of Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking and ISTH SSC to harmonize enzyme-linked immunosorbent assay and non-enzyme-linked immunosorbent assay antiphospholipid antibody tests: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies<\/a> <a href=\"#cef8f728-df1b-4004-b67c-8ba0f37ebc6d-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 2 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"4dfe3542-aee0-4f15-b5bc-3426cc197f65\"><a href=\"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/10.1002\/advs.202415291\" target=\"_blank\" rel=\"noreferrer noopener\">Chen, <em>et al.<\/em> (2025). Identification of Three Distinct Subgroups in Antiphospholipid Syndrome: Implication for Sex Differences and Prognostic Outcomes from a Multicenter Study<\/a> <a href=\"#4dfe3542-aee0-4f15-b5bc-3426cc197f65-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 3 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"352b2b96-b8e0-4a7e-b323-6e7b857157a1\"><a href=\"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-025-07471-w\" target=\"_blank\" rel=\"noreferrer noopener\">Murvai, <em>et al.<\/em> (2025). Antiphospholipid syndrome in pregnancy: a comprehensive literature review<\/a> <a href=\"#352b2b96-b8e0-4a7e-b323-6e7b857157a1-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 4 navigieren\">\u21a9\ufe0e<\/a><\/li><li id=\"924b3cd8-f300-46db-af18-4d0b48e3e240\"><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9658219\/\">Anunciaci\u00f3n-Llunell, <em>et al.<\/em> (2025). Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome<\/a> <a href=\"#924b3cd8-f300-46db-af18-4d0b48e3e240-link\" aria-label=\"Zur Fu\u00dfnotenreferenz 5 navigieren\">\u21a9\ufe0e<\/a><\/li><\/ol>\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Das Antiphospholipid-Syndrom (APS) ist ein bedeutender Risikofaktor f\u00fcr Schwangerschaftskomplikationen, doch seine Diagnose bleibt eine Herausforderung. J\u00fcngste Fortschritte in der APS-Diagnostik liefern tiefere Einblicke in seine Rolle bei wiederholtem Schwangerschaftsverlust und Pr\u00e4eklampsie. Durch innovative Biomarkerforschung und verfeinerte Testmethoden wird die Diagnosesicherheit verbessert, sodass Risikopatientinnen pr\u00e4ziser identifiziert und gezielt behandelt werden k\u00f6nnen. Erfahren Sie mehr \u00fcber die neuesten Entwicklungen in der APS-Diagnostik und deren Auswirkungen auf die m\u00fctterliche und fetale Gesundheit.<\/p>\n","protected":false},"author":3,"featured_media":18543,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"[{\"content\":\"<a href=\\\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37635643\/\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Barbhaiya, <em>et al.<\/em> (2024). The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria<\/a>\",\"id\":\"1a6564a0-1e4e-46b7-93a4-03227522d30f\"},{\"content\":\"<a href=\\\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39395544\/\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Meroni, <em>et al.<\/em> (2025). American College of Rheumatology\/European League Against Rheumatism antiphospholipid syndrome classification criteria solid phase-based antiphospholipid antibody domain-collaborative efforts of Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking and ISTH SSC to harmonize enzyme-linked immunosorbent assay and non-enzyme-linked immunosorbent assay antiphospholipid antibody tests: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies<\/a>\",\"id\":\"cef8f728-df1b-4004-b67c-8ba0f37ebc6d\"},{\"content\":\"<a href=\\\"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/10.1002\/advs.202415291\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Chen, <em>et al.<\/em> (2025). Identification of Three Distinct Subgroups in Antiphospholipid Syndrome: Implication for Sex Differences and Prognostic Outcomes from a Multicenter Study<\/a>\",\"id\":\"4dfe3542-aee0-4f15-b5bc-3426cc197f65\"},{\"content\":\"<a href=\\\"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-025-07471-w\\\" target=\\\"_blank\\\" rel=\\\"noreferrer noopener\\\">Murvai, <em>et al.<\/em> (2025). Antiphospholipid syndrome in pregnancy: a comprehensive literature review<\/a>\",\"id\":\"352b2b96-b8e0-4a7e-b323-6e7b857157a1\"},{\"content\":\"<a href=\\\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9658219\/\\\">Anunciaci\u00f3n-Llunell, <em>et al.<\/em> (2025). Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome<\/a>\",\"id\":\"924b3cd8-f300-46db-af18-4d0b48e3e240\"}]"},"categories":[177],"tags":[],"class_list":["post-18762","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-products-news-de"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neue diagnostische Erkenntnisse beim Antiphospholipid-Syndrom (APS) und Schwangerschaft<\/title>\n<meta name=\"description\" content=\"Entdecken Sie die neuesten Fortschritte in der Diagnostik des Antiphospholipid-Syndroms (APS) und deren Auswirkungen auf Schwangerschaften. Erfahren Sie, wie verbesserte Testmethoden die Risikobewertung optimieren.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neue diagnostische Erkenntnisse beim Antiphospholipid-Syndrom (APS) und Schwangerschaft\" \/>\n<meta property=\"og:description\" content=\"Entdecken Sie die neuesten Fortschritte in der Diagnostik des Antiphospholipid-Syndroms (APS) und deren Auswirkungen auf Schwangerschaften. Erfahren Sie, wie verbesserte Testmethoden die Risikobewertung optimieren.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/\" \/>\n<meta property=\"og:site_name\" content=\"Medipan &amp; GA Generic Assays\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/people\/Medipan-GA-Generic-Assays\/pfbid02ULuoTqAH3VaVSiKK1yK6und3uDLDWT5sPtqVXyQHcW1QBfBX1ywC47X62DBGZgril\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T14:35:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T09:28:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/AdobeStock_376284351-scaled-e1743082621518.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Stefano Frasca\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Stefano Frasca\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"4\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\\\/\"},\"author\":{\"name\":\"Dr. Stefano Frasca\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#\\\/schema\\\/person\\\/79bd5fbc4d559d6bf0daa2d30d420904\"},\"headline\":\"Neue diagnostische Erkenntnisse beim Antiphospholipid-Syndrom (APS) und Schwangerschaft\",\"datePublished\":\"2025-03-26T14:35:29+00:00\",\"dateModified\":\"2025-11-26T09:28:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\\\/\"},\"wordCount\":675,\"publisher\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/AdobeStock_376284351-scaled-e1743082621518.jpeg\",\"articleSection\":[\"Produktneuigkeiten\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\\\/\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\\\/\",\"name\":\"Neue diagnostische Erkenntnisse beim Antiphospholipid-Syndrom (APS) und Schwangerschaft\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/AdobeStock_376284351-scaled-e1743082621518.jpeg\",\"datePublished\":\"2025-03-26T14:35:29+00:00\",\"dateModified\":\"2025-11-26T09:28:27+00:00\",\"description\":\"Entdecken Sie die neuesten Fortschritte in der Diagnostik des Antiphospholipid-Syndroms (APS) und deren Auswirkungen auf Schwangerschaften. Erfahren Sie, wie verbesserte Testmethoden die Risikobewertung optimieren.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.medipan.de\\\/de\\\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/AdobeStock_376284351-scaled-e1743082621518.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/AdobeStock_376284351-scaled-e1743082621518.jpeg\",\"width\":2560,\"height\":1707,\"caption\":\"Schwangere Frau h\u00e4lt herzf\u00f6rmige H\u00e4nde auf die Haut ihres Babybauchs.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neue diagnostische Erkenntnisse beim Antiphospholipid-Syndrom (APS) und Schwangerschaft\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/\",\"name\":\"Medipan.de\",\"description\":\"Your reliable partner in autoimmune diagnostics\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#organization\",\"name\":\"Medipan GmbH & GA Generic Assays GmbH\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2021\\\/01\\\/logo_transparent.png\",\"contentUrl\":\"https:\\\/\\\/www.medipan.de\\\/wp-content\\\/uploads\\\/2021\\\/01\\\/logo_transparent.png\",\"width\":108,\"height\":49,\"caption\":\"Medipan GmbH & GA Generic Assays GmbH\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/people\\\/Medipan-GA-Generic-Assays\\\/pfbid02ULuoTqAH3VaVSiKK1yK6und3uDLDWT5sPtqVXyQHcW1QBfBX1ywC47X62DBGZgril\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/medipan-generic-assays-gmbh\\\/?originalSubdomain=de\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCFTKVg_v7n57CG7i9rPv-NQ\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.medipan.de\\\/de\\\/#\\\/schema\\\/person\\\/79bd5fbc4d559d6bf0daa2d30d420904\",\"name\":\"Dr. Stefano Frasca\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g\",\"caption\":\"Dr. Stefano Frasca\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neue diagnostische Erkenntnisse beim Antiphospholipid-Syndrom (APS) und Schwangerschaft","description":"Entdecken Sie die neuesten Fortschritte in der Diagnostik des Antiphospholipid-Syndroms (APS) und deren Auswirkungen auf Schwangerschaften. Erfahren Sie, wie verbesserte Testmethoden die Risikobewertung optimieren.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/","og_locale":"de_DE","og_type":"article","og_title":"Neue diagnostische Erkenntnisse beim Antiphospholipid-Syndrom (APS) und Schwangerschaft","og_description":"Entdecken Sie die neuesten Fortschritte in der Diagnostik des Antiphospholipid-Syndroms (APS) und deren Auswirkungen auf Schwangerschaften. Erfahren Sie, wie verbesserte Testmethoden die Risikobewertung optimieren.","og_url":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/","og_site_name":"Medipan &amp; GA Generic Assays","article_publisher":"https:\/\/www.facebook.com\/people\/Medipan-GA-Generic-Assays\/pfbid02ULuoTqAH3VaVSiKK1yK6und3uDLDWT5sPtqVXyQHcW1QBfBX1ywC47X62DBGZgril\/","article_published_time":"2025-03-26T14:35:29+00:00","article_modified_time":"2025-11-26T09:28:27+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/AdobeStock_376284351-scaled-e1743082621518.jpeg","type":"image\/jpeg"}],"author":"Dr. Stefano Frasca","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Dr. Stefano Frasca","Gesch\u00e4tzte Lesezeit":"4\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/#article","isPartOf":{"@id":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/"},"author":{"name":"Dr. Stefano Frasca","@id":"https:\/\/www.medipan.de\/de\/#\/schema\/person\/79bd5fbc4d559d6bf0daa2d30d420904"},"headline":"Neue diagnostische Erkenntnisse beim Antiphospholipid-Syndrom (APS) und Schwangerschaft","datePublished":"2025-03-26T14:35:29+00:00","dateModified":"2025-11-26T09:28:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/"},"wordCount":675,"publisher":{"@id":"https:\/\/www.medipan.de\/de\/#organization"},"image":{"@id":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/AdobeStock_376284351-scaled-e1743082621518.jpeg","articleSection":["Produktneuigkeiten"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/","url":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/","name":"Neue diagnostische Erkenntnisse beim Antiphospholipid-Syndrom (APS) und Schwangerschaft","isPartOf":{"@id":"https:\/\/www.medipan.de\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/#primaryimage"},"image":{"@id":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/AdobeStock_376284351-scaled-e1743082621518.jpeg","datePublished":"2025-03-26T14:35:29+00:00","dateModified":"2025-11-26T09:28:27+00:00","description":"Entdecken Sie die neuesten Fortschritte in der Diagnostik des Antiphospholipid-Syndroms (APS) und deren Auswirkungen auf Schwangerschaften. Erfahren Sie, wie verbesserte Testmethoden die Risikobewertung optimieren.","breadcrumb":{"@id":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/#primaryimage","url":"https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/AdobeStock_376284351-scaled-e1743082621518.jpeg","contentUrl":"https:\/\/www.medipan.de\/wp-content\/uploads\/2025\/03\/AdobeStock_376284351-scaled-e1743082621518.jpeg","width":2560,"height":1707,"caption":"Schwangere Frau h\u00e4lt herzf\u00f6rmige H\u00e4nde auf die Haut ihres Babybauchs."},{"@type":"BreadcrumbList","@id":"https:\/\/www.medipan.de\/de\/new-diagnostic-insights-in-antiphospholipid-syndrome-aps-and-pregnancy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.medipan.de\/de\/"},{"@type":"ListItem","position":2,"name":"Neue diagnostische Erkenntnisse beim Antiphospholipid-Syndrom (APS) und Schwangerschaft"}]},{"@type":"WebSite","@id":"https:\/\/www.medipan.de\/de\/#website","url":"https:\/\/www.medipan.de\/de\/","name":"Medipan.de","description":"Your reliable partner in autoimmune diagnostics","publisher":{"@id":"https:\/\/www.medipan.de\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.medipan.de\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.medipan.de\/de\/#organization","name":"Medipan GmbH & GA Generic Assays GmbH","url":"https:\/\/www.medipan.de\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.medipan.de\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.medipan.de\/wp-content\/uploads\/2021\/01\/logo_transparent.png","contentUrl":"https:\/\/www.medipan.de\/wp-content\/uploads\/2021\/01\/logo_transparent.png","width":108,"height":49,"caption":"Medipan GmbH & GA Generic Assays GmbH"},"image":{"@id":"https:\/\/www.medipan.de\/de\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/people\/Medipan-GA-Generic-Assays\/pfbid02ULuoTqAH3VaVSiKK1yK6und3uDLDWT5sPtqVXyQHcW1QBfBX1ywC47X62DBGZgril\/","https:\/\/www.linkedin.com\/company\/medipan-generic-assays-gmbh\/?originalSubdomain=de","https:\/\/www.youtube.com\/channel\/UCFTKVg_v7n57CG7i9rPv-NQ"]},{"@type":"Person","@id":"https:\/\/www.medipan.de\/de\/#\/schema\/person\/79bd5fbc4d559d6bf0daa2d30d420904","name":"Dr. Stefano Frasca","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d0184820b8afa2a8d194b02b85fb7b9f6430623d6e8f2b5deabba7d3c67bc75f?s=96&d=mm&r=g","caption":"Dr. Stefano Frasca"}}]}},"_links":{"self":[{"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/posts\/18762","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/comments?post=18762"}],"version-history":[{"count":9,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/posts\/18762\/revisions"}],"predecessor-version":[{"id":104513,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/posts\/18762\/revisions\/104513"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/media\/18543"}],"wp:attachment":[{"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/media?parent=18762"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/categories?post=18762"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.medipan.de\/de\/wp-json\/wp\/v2\/tags?post=18762"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}